Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Dec 1;151(11):1978-1988.
doi: 10.1002/ijc.34166. Epub 2022 Jul 14.

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

Cécile Torregrosa  1 , Simon Pernot  2 , Pauline Vaflard  3 , Audrey Perret  4 , Christophe Tournigand  5 , Violaine Randrian  6 , Solene Doat  7 , Cindy Neuzillet  8 , Valérie Moulin  9 , Morgane Stouvenot  10 , Gael Roth  11 , Tiffany Darbas  12 , Benjamin Auberger  13 , Tiphaine Godet  14 , Marion Jaffrelot  15 , Aurélien Lambert  16 , Olivier Dubreuil  17 , Cassandre Gluszak  18 , Alice Bernard-Tessier  19 , Anthony Turpin  20 , Lola-Jade Palmieri  21 , Olivier Bouche  22 , Gael Goujon  23 , Thierry Lecomte  24 , David Sefrioui  25 , Christophe Locher  26 , Lucien Grados  27 , Pauline Gignoux  28 , Stéphanie Trager  29 , Elise Nassif  30 , Angélique Saint  31 , Pascal Hammel  32 , Cédric Lecaille  33 , Mathilde Bureau  34 , Marine Perrier  22 , Damien Botsen  22 , Vincent Bourgeois  35 , Julien Taieb  1 , Edouard Auclin  1
Affiliations
Multicenter Study

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

Cécile Torregrosa et al. Int J Cancer. .

Abstract

After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2 years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6) (P < .0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.

Keywords: aflibercept; bevacizumab; chemotherapy; metastatic colorectal cancer.

PubMed Disclaimer

References

REFERENCES

    1. Brenner H, Kloor M, Pox C. Colorectal cancer. Lancet. 2014;383(9927):1490-1502.
    1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
    1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
    1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1-iii9.
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.

Publication types

MeSH terms